Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

INTEGRATED LABS

NPI: 1306125778 · WEST LINN, OR 97068 · Clinical Medical Laboratory · NPI assigned 08/16/2011

$213K
Total Medicaid Paid
4,829
Total Claims
4,507
Beneficiaries
3
Codes Billed
2020-02
First Month
2024-11
Last Month

Provider Details

Authorized OfficialMORSE, STANLEY (OWNER)
NPI Enumeration Date08/16/2011

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2020 376 $13K
2021 1,249 $52K
2022 1,062 $38K
2023 1,126 $54K
2024 1,016 $56K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 4,152 4,037 $188K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 474 272 $20K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 203 198 $5K